Mechanism, Function, and Exploitation of Influenza A Virus-Activated Cell Death
Mechanism, Function, and Exploitation of Influenza A Virus-Activated Cell Death
批准号:
10247652
负责人:
SIDDHARTH BALACHANDRAN
金额:
$57.79万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-25 至 2022-08-31
关键词:
Adult Respiratory Distress SyndromeAnimalsApoptosisAvian InfluenzaAvian Influenza A VirusBindingCell Culture TechniquesCell DeathCell Death Signaling ProcessCellsCessation of lifeClinicalDouble-Stranded RNAEpithelialEpithelial CellsFDA approvedFibroblastsGoalsHandHost Defense MechanismHumanImmunologicsIndividualInfectionInfluenza A Virus, H5N1 SubtypeInfluenza A Virus, H7N9 SubtypeInfluenza A virusKnowledgeLeadLeftLower respiratory tract structureLungMediatingModelingMolecularMusNecrosisPathogenesisPathogenicityPathologicPathway interactionsPharmacologyPhosphotransferasesPredispositionProteinsPublic HealthRIPK3 geneRNARNA VirusesReporterRoleSignal PathwaySignal TransductionSystemTestingTherapeuticTimeTissuesViral PathogenesisVirulentVirusVirus DiseasesVirus Replicationairway epitheliumbasecell typegenomic RNAimmunopathologyin vivoinfluenza virus straininhibitor/antagonistkinase inhibitorlung injurymacrophagemortalitymouse modelnovelnovel therapeuticsnucleic acid binding proteinpandemic diseasepreventrespiratorysensorviral RNA
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Influenza A viruses (IAV) kill most of the cell types in which they replicate, both in cell culture and in infected
lungs in vivo. While regulated cell death represents a host defense mechanism that limits both virus spread and
host immunopathology early in an infection, unbridled cell death, particularly necrosis, can lead to severe
degradation of bronchioalveolar epithelia and consequent mortality despite control of virus replication in vivo.
Indeed, severe illness following infection with highly pathogenic strains of IAV is well-correlated with widespread
pulmonary epithelial cell death and bronchioalveolar tissue damage in humans. Despite this, remarkably little is
known of the molecular mechanisms by which IAV activates cell death in relevant lung cell types. Thus (1)
understanding the mechanisms by which IAV triggers cell death, (2) determining the identity and importance of
lung cell types that die by these mechanisms during IAV infection in vivo; and (3) determining if pharmacological
manipulation of cell death represents a new therapeutic entry-point for respiratory IAV are each important unmet
objectives. We have recently discovered a mechanism of cell death that appears to account for almost all IAV-
activated death in infected airway epithelial cells. This pathway is initiated when the protein DAI senses IAV
genomic RNA and nucleates the kinase RIPK3. RIPK3 then activates parallel pathways of programmed necrosis
(necroptosis), as well as apoptosis. Necroptosis downstream of RIPK3 relies on MLKL and apoptosis on FADD,
such that deletion of DAI, RIPK3, or MLKL+FADD renders mice extraordinarily susceptible to respiratory IAV
replication and lethality. Remarkably, eliminating MLKL alone has no discernible effect, demonstrating that the
FADD apoptosis axis can fully compensate for loss of MLKL and necroptosis. To our knowledge, these findings
represent the first description of a dedicated IAV activated cell death pathway, the first implication of DAI as a
sensor of RNA viruses, and the first identification of a virus that triggers both apoptosis and necroptosis
downstream of RIPK3. The redundancy of necroptosis with apoptosis to IAV clearance also provides an
unexpected therapeutic opportunity in cases where necrotic death is implicated in IAV pathogenesis. Based on
these and other observations, the goals of this proposal are to: (1) identify the molecular mechanisms by which
the DAI-RIPK3 axis recognizes IAV and activates cell death; (2) employ cutting-edge mouse reporter models to
isolate and identify lung cell types that succumb to IAV by RIPK3-driven apoptosis versus necroptosis, and
determine in which of these cell types is RIPK3 signaling important for virus control; and (3) test if selective
blockade of necroptosis will have clinical benefit following infection with highly-pathogenic strains of IAV.
Successful completion of these Aims has the potential to transform our understanding of IAV pathogenesis, with
immediate clinical ramifications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Small-molecule exploitation of ZBP1-driven nuclear necroptosis for cancer immunotherapy
-
批准号:10586659
-
项目类别:
-
资助金额:$75.9万
-
财政年份:2023
-
负责人:SIDDHARTH BALACHANDRAN
-
依托单位:
Harnessing ZBP1-triggered cell death to enhance influenza vaccine responsiveness
-
批准号:10884586
-
项目类别:
-
资助金额:$83.35万
-
财政年份:2023
-
负责人:SIDDHARTH BALACHANDRAN
-
依托单位:
Role of ZBP1 in pathogenesis of Salmonella biofilms
-
批准号:10658383
-
项目类别:
-
资助金额:$84.61万
-
财政年份:2023
-
负责人:SIDDHARTH BALACHANDRAN
-
依托单位:
Necroptosis in SARS-CoV-2 pathogenesis, evolution, and therapy
-
批准号:10557863
-
项目类别:
-
资助金额:$23.3万
-
财政年份:2022
-
负责人:SIDDHARTH BALACHANDRAN
-
依托单位:
Necroptosis in SARS-CoV-2 pathogenesis, evolution, and therapy
-
批准号:10433040
-
项目类别:
-
资助金额:$28.0万
-
财政年份:2022
-
负责人:SIDDHARTH BALACHANDRAN
-
依托单位:
Harnessing ZBP1-driven cell death to improve influenza vaccine efficacy
-
批准号:10455196
-
项目类别:
-
资助金额:$84.79万
-
财政年份:2021
-
负责人:SIDDHARTH BALACHANDRAN
-
依托单位:
Targeting RIPK3 in Flu-Associated Lung Injury
-
批准号:10020307
-
项目类别:
-
资助金额:$67.89万
-
财政年份:2019
-
负责人:SIDDHARTH BALACHANDRAN
-
依托单位:
Targeting RIPK3 in Flu-Associated Lung Injury
-
批准号:10470746
-
项目类别:
-
资助金额:$73.17万
-
财政年份:2019
-
负责人:SIDDHARTH BALACHANDRAN
-
依托单位:
Targeting RIPK3 in Flu-Associated Lung Injury
-
批准号:10689229
-
项目类别:
-
资助金额:$70.2万
-
财政年份:2019
-
负责人:SIDDHARTH BALACHANDRAN
-
依托单位:
Targeting RIPK3 in Flu-Associated Lung Injury
-
批准号:10238084
-
项目类别:
-
资助金额:$78.93万
-
财政年份:2019
-
负责人:SIDDHARTH BALACHANDRAN
-
依托单位:
Mechanism, Function, and Exploitation of Influenza A Virus-Activated Cell Death
-
批准号:9761976
-
项目类别:
-
资助金额:$66.71万
-
财政年份:2017
-
负责人:SIDDHARTH BALACHANDRAN
-
依托单位:
Mechanism, Function, and Exploitation of Influenza A Virus-Activated Cell Death
-
批准号:10610449
-
项目类别:
-
资助金额:$72.03万
-
财政年份:2017
-
负责人:SIDDHARTH BALACHANDRAN
-
依托单位:
Mechanism, Function, and Exploitation of Influenza A Virus-Activated Cell Death
-
批准号:10446481
-
项目类别:
-
资助金额:$74.23万
-
财政年份:2017
-
负责人:SIDDHARTH BALACHANDRAN
-
依托单位:
RIP1/3 Kinases as New Targets in Malignant Mesothelioma
-
批准号:8799710
-
项目类别:
-
资助金额:$41.47万
-
财政年份:2015
-
负责人:SIDDHARTH BALACHANDRAN
-
依托单位:
Control of interferon-activated necrosis by a virus-triggered FADD checkpoint
-
批准号:8770320
-
项目类别:
-
资助金额:$22.31万
-
财政年份:2014
-
负责人:SIDDHARTH BALACHANDRAN
-
依托单位:
Interferon Activated Necroptosis as a New Therapeutic Avenue for Kidney Cancer
-
批准号:8829193
-
项目类别:
-
资助金额:$37.04万
-
财政年份:2014
-
负责人:SIDDHARTH BALACHANDRAN
-
依托单位:
Picornavirus-initiated inflamation: novel parallels from Drosophila
-
批准号:8444160
-
项目类别:
-
资助金额:$22.31万
-
财政年份:2013
-
负责人:SIDDHARTH BALACHANDRAN
-
依托单位:
Picornavirus-initiated inflamation: novel parallels from Drosophila
-
批准号:8608479
-
项目类别:
-
资助金额:$26.78万
-
财政年份:2013
-
负责人:SIDDHARTH BALACHANDRAN
-
依托单位:
Blood Cell Development and Function Program (02)
-
批准号:10427547
-
项目类别:
-
资助金额:$1.43万
-
财政年份:1997
-
负责人:SIDDHARTH BALACHANDRAN
-
依托单位:
Blood Cell Development and Function Program (02)
-
批准号:9147891
-
项目类别:
-
资助金额:$3.18万
-
财政年份:--
-
负责人:SIDDHARTH BALACHANDRAN
-
依托单位:
海外基金